VECT - VectivBio - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

846.2M

Cash

221.4M

Avg Qtr Burn

-14.06M

Short % of Float

0.25%

Insider Ownership

4.50%

Institutional Own.

83.80%

Qtr Updated

12/31/22

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Apraglutide (agonist of the GLP-2 receptor) Details Short bowel syndrome Big Mover™ Suspected Mover™ Susp. Mover™	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Apraglutide (agonist of the GLP-2 receptor) Details Acute graft-versus host disease	Phase 2 Interim update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Apraglutide (agonist of the GLP-2 receptor) Details Short bowel syndrome, Short bowel syndrome with colon-in-continuity	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.